Physician profile
Amy Blake
NPI 1386148708
$1,229.81
in general payments reported to CMS, 2019-2025
14 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.95 · 2021: $99.99 · 2022: $123 · 2023: $323 · 2024: $172 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $327.38 | 2020-2023 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $257.40 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $159.46 | 2022-2025 | |
| Pfizer INC. | $80.80 | 2023-2025 | |
| Amgen INC. | $73.00 | 2024 | Otezla |
| Genzyme Corporation | $68.75 | 2025 | |
| Kerecis Limited | $45.49 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| E.R. Squibb & Sons, L.L.C. | $40.64 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $38.85 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $37.99 | 2023-2024 | Zoryve |
| Organon LLC | $35.00 | 2025 | Vtama |
| Lilly USA, LLC | $29.65 | 2025 | Ebglyss, Taltz |
| Organogenesis INC. | $20.28 | 2025 | Puraply Wound Matrix |
| Ucb, INC. | $15.12 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.